CY1123707T1 - Νεοι αναστολεις καλλικρεϊνης 7 - Google Patents

Νεοι αναστολεις καλλικρεϊνης 7

Info

Publication number
CY1123707T1
CY1123707T1 CY20201101150T CY201101150T CY1123707T1 CY 1123707 T1 CY1123707 T1 CY 1123707T1 CY 20201101150 T CY20201101150 T CY 20201101150T CY 201101150 T CY201101150 T CY 201101150T CY 1123707 T1 CY1123707 T1 CY 1123707T1
Authority
CY
Cyprus
Prior art keywords
inhibitors
klk7
prevention
treatment
kallikrein
Prior art date
Application number
CY20201101150T
Other languages
English (en)
Inventor
Marcel Linschoten
Original Assignee
Sixera Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixera Pharma Ab filed Critical Sixera Pharma Ab
Publication of CY1123707T1 publication Critical patent/CY1123707T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μεθόδους για την αναστολή της δράσης της ανθρώπινης καλλικρεΐνης 7 (KLK7) (γνωστή ως χυμοθρυπτικό ένζυμο κεράτινης στιβάδας (SCCE) σερινοπρωτεάσης). Η εφεύρεση σχετίζεται περαιτέρω με τη χρήση αναστολέων της KLK7 του τύπου Ι για τη θεραπεία και την πρόληψη νόσων, πιο συγκεκριμένα για τη θεραπεία και την πρόληψη δερματικών νόσων. Η εφεύρεση προβλέπει επίσης νέες ενώσεις που έχει αποδεχθεί ότι είναι αναστολείς της KLK7.
CY20201101150T 2014-01-23 2020-12-04 Νεοι αναστολεις καλλικρεϊνης 7 CY1123707T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1430004 2014-01-23
PCT/SE2015/050060 WO2015112079A1 (en) 2014-01-23 2015-01-22 New kallikrein 7 inhibitors

Publications (1)

Publication Number Publication Date
CY1123707T1 true CY1123707T1 (el) 2022-03-24

Family

ID=53681745

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101150T CY1123707T1 (el) 2014-01-23 2020-12-04 Νεοι αναστολεις καλλικρεϊνης 7

Country Status (16)

Country Link
US (1) US9744148B2 (el)
EP (1) EP3097084B1 (el)
JP (2) JP6552010B2 (el)
CN (1) CN106132940B (el)
AU (1) AU2015209759B2 (el)
CA (1) CA2934024C (el)
CY (1) CY1123707T1 (el)
DK (1) DK3097084T3 (el)
ES (1) ES2834851T3 (el)
HR (1) HRP20201915T1 (el)
HU (1) HUE052990T2 (el)
LT (1) LT3097084T (el)
PT (1) PT3097084T (el)
RS (1) RS61142B1 (el)
SI (1) SI3097084T1 (el)
WO (1) WO2015112079A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61142B1 (sr) * 2014-01-23 2020-12-31 Sixera Pharma Ab Novi inhibitori kalikreina 7
EP3305781A1 (en) * 2016-10-07 2018-04-11 Deutsches Krebsforschungszentrum Chemical substances which inhibit the enzymatic activity of human kallikrein-related peptidase 6 (klk6)
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514355A1 (fr) * 1981-10-14 1983-04-15 Fabre Sa Pierre Derives de biphenyl alcoyl carboxylates, leur procede de preparation et leur utilisation comme medicaments
AU2003231865A1 (en) 2002-05-31 2003-12-19 Genzyme Corporation Alpha acyloxyacetamides for kallikrein and urokinase inhibition
CA2525383C (en) 2003-06-06 2012-03-06 Arexis Ab Use of heterocyclic compounds as scce inhibitors
CA2670458C (en) * 2006-11-23 2016-01-05 Vib Vzw Activators of lateral root formation
KR20100027159A (ko) 2007-06-28 2010-03-10 노파르티스 아게 칼리크레인 7 조절제
AU2008290567B2 (en) 2007-08-17 2011-05-12 Novartis Ag Cyclic depsipeptides
JP5401459B2 (ja) * 2007-08-17 2014-01-29 ノバルティス アーゲー カリクレイン７を阻害するための環状デプシペプチドの使用
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
EP2545916A1 (en) 2011-07-15 2013-01-16 Universite Pierre Et Marie Curie - Paris 6 Use of coumarin derivatives for the preparation of drugs for treating skin diseases
RS61142B1 (sr) * 2014-01-23 2020-12-31 Sixera Pharma Ab Novi inhibitori kalikreina 7

Also Published As

Publication number Publication date
EP3097084A4 (en) 2017-10-04
PT3097084T (pt) 2020-12-09
HUE052990T2 (hu) 2021-05-28
DK3097084T3 (da) 2020-12-21
EP3097084B1 (en) 2020-09-30
CN106132940A (zh) 2016-11-16
JP2019163296A (ja) 2019-09-26
AU2015209759B2 (en) 2018-11-29
EP3097084A1 (en) 2016-11-30
AU2015209759A1 (en) 2016-07-07
WO2015112079A1 (en) 2015-07-30
CA2934024C (en) 2022-08-23
ES2834851T3 (es) 2021-06-18
JP6552010B2 (ja) 2019-07-31
US20170000753A1 (en) 2017-01-05
HRP20201915T1 (hr) 2021-01-22
SI3097084T1 (sl) 2021-01-29
LT3097084T (lt) 2020-12-28
US9744148B2 (en) 2017-08-29
RS61142B1 (sr) 2020-12-31
JP6932386B2 (ja) 2021-09-08
CA2934024A1 (en) 2015-07-30
CN106132940B (zh) 2019-04-23
JP2017505299A (ja) 2017-02-16

Similar Documents

Publication Publication Date Title
CY1123707T1 (el) Νεοι αναστολεις καλλικρεϊνης 7
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1123477T1 (el) Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
EA201891526A2 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201500362A1 (ru) Ингибиторы rho-киназы
NZ724691A (en) Quinoline derivatives as smo inhibitors
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201590987A1 (ru) Соединения и способы их применения
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
MX2017003624A (es) Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2019001011A (es) Compuestos farmaceuticos.
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения